Lomina SARS-CoV-2 Antigen LTX Test kits, which allow rapid testing for infection by the Covid-19 virus, have been successfully approved in Germany and registered in the BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) database.
The BfArM is the Federal Institute for Drugs and Medical Devices and acts as a higher independent federal body under the Federal Ministry of Health. Its tasks include monitoring the adherence to high drug safety standards and protection of patient safety in the Federal Republic of Germany.
Lomina SARS-CoV-2 Antigen LTX Tests are antigen tests manufactured in the European Union. The test is easy to apply and provides rapid results. The tests undergo regular testing by certified laboratories and are highly sensitive and specific.
The BfArM registered the Lomina self-test kit as an approved Covid-19 antigen test intended for direct SARS-CoV-2 coronavirus pathogen detection. This means that these tests, which are developed within the terms of a Czech-Swiss partnership, have now been registered in another register of reliable antigen tests.
